Screener
Castle Biosciences CSTL Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| ASSETS | March 31, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Current portion of long-term debt | 1,667 | 417 |
| Other accrued and current liabilities | 10,691 | 8,937 |
| Total current liabilities | 48,761 | 68,677 |
| Long-term debt | 8,399 | 9,640 |
| Noncurrent portion of contingent consideration | 1,500 | 1,500 |
| Noncurrent operating lease liabilities | 25,116 | 25,217 |
| Noncurrent finance lease liabilities | 288 | 314 |
| Deferred tax liability | 2,325 | 2,335 |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's long-term debt?
- Castle Biosciences (CSTL) reported long-term debt of $8.4M in Q1 2026.
- How has Castle Biosciences's long-term debt changed year-over-year?
- Castle Biosciences's long-term debt decreased by 5.9% year-over-year, from $8.92M to $8.4M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Castle Biosciences's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude